30 results
8-K
EX-99.1
LIANY
LianBio
1 May 23
Regulation FD Disclosure
7:28am
that targets the excessive contractility and impaired relaxation, myocardial energetics and compliance, with the intent of correcting the abnormal function
8-K
EX-99.1
LIANY
LianBio
21 Apr 23
Other Events
4:13pm
Medical College Hospital, and Principal Investigator, EXPLORER-CN. “As the first therapy that targets the pathophysiology of disease, mavacamten holds
8-K
EX-99.2
omglk a3l3yq5tn
10 Nov 22
LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:16pm
8-K
EX-99.2
ba4xxcq 1k8piey1gnhk
11 Aug 22
LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:30pm
8-K
EX-99.2
uuusik7d6jp4fqv b1
12 May 22
LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update
9:15am
10-K
jxt52abbn6 48g
31 Mar 22
Annual report
8:55am
8-K
EX-99.1
d446o6u
2 Mar 22
Regulation FD Disclosure
4:42pm
10-Q
3oy 6jz6lcr
9 Dec 21
Quarterly report
5:24pm
424B4
9egef8l
2 Nov 21
Prospectus supplement with pricing info
4:02pm
S-1/A
2obnwux5uz0d3px
8 Oct 21
IPO registration (amended)
5:09pm